Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-Dose IL-2 with Lymphodepletion in Metastatic Melanoma
NCT00085423Phase 2Completed
- Sponsor
- Dartmouth Health
- Start
- Feb 2004
- Primary completion
- Dec 2008
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of aldesleukin in melanoma, sponsored by Dartmouth Health. Primary endpoints: Objective Response Rate at 12 weeks and Feasibility of Regimen. Started Feb 2004; status: completed.
02
Drugs
aldesleukin
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT00085423.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00085423.